NOK 1.32
(-0.75%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 2.99 Million NOK | 0.0% |
2022 | - NOK | 0.0% |
2021 | - NOK | 0.0% |
2020 | - NOK | 0.0% |
2019 | - NOK | 0.0% |
2018 | - NOK | 0.0% |
2017 | - NOK | 0.0% |
2016 | - NOK | 0.0% |
2015 | - NOK | 0.0% |
2014 | - NOK | 0.0% |
2013 | - NOK | 0.0% |
2012 | - NOK | -100.0% |
2011 | 7.42 Million NOK | -28.93% |
2010 | 10.44 Million NOK | 21.27% |
2009 | 8.61 Million NOK | 16.9% |
2008 | 7.36 Million NOK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 1.71 Million NOK | 33.15% |
2024 Q2 | 1.71 Million NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2023 FY | - NOK | 0.0% |
2023 Q4 | 1.28 Million NOK | 0.0% |
2023 Q3 | 1.28 Million NOK | 0.0% |
2023 Q1 | - NOK | 0.0% |
2022 Q4 | - NOK | 0.0% |
2022 FY | - NOK | 0.0% |
2022 Q1 | - NOK | 0.0% |
2022 Q2 | - NOK | 0.0% |
2022 Q3 | - NOK | 0.0% |
2021 Q4 | - NOK | 0.0% |
2021 Q2 | - NOK | 0.0% |
2021 Q1 | - NOK | 0.0% |
2021 FY | - NOK | 0.0% |
2021 Q3 | - NOK | 0.0% |
2020 Q2 | - NOK | 0.0% |
2020 Q3 | - NOK | 0.0% |
2020 Q4 | - NOK | 0.0% |
2020 FY | - NOK | 0.0% |
2020 Q1 | - NOK | 0.0% |
2019 FY | - NOK | 0.0% |
2019 Q2 | - NOK | 0.0% |
2019 Q4 | - NOK | 0.0% |
2019 Q3 | - NOK | 0.0% |
2019 Q1 | - NOK | 0.0% |
2018 FY | - NOK | 0.0% |
2018 Q4 | - NOK | 0.0% |
2018 Q3 | - NOK | 0.0% |
2018 Q2 | - NOK | 0.0% |
2018 Q1 | - NOK | 0.0% |
2017 Q4 | - NOK | 0.0% |
2017 FY | - NOK | 0.0% |
2017 Q1 | - NOK | 0.0% |
2017 Q2 | - NOK | 0.0% |
2017 Q3 | - NOK | 0.0% |
2016 Q1 | - NOK | 0.0% |
2016 FY | - NOK | 0.0% |
2016 Q4 | - NOK | 0.0% |
2016 Q3 | - NOK | 0.0% |
2016 Q2 | - NOK | 0.0% |
2015 Q3 | - NOK | 0.0% |
2015 FY | - NOK | 0.0% |
2015 Q1 | - NOK | 0.0% |
2015 Q2 | - NOK | 0.0% |
2015 Q4 | - NOK | 0.0% |
2014 Q1 | - NOK | 0.0% |
2014 Q2 | - NOK | 0.0% |
2014 Q3 | - NOK | 0.0% |
2014 Q4 | - NOK | 0.0% |
2014 FY | - NOK | 0.0% |
2013 Q1 | - NOK | 0.0% |
2013 Q2 | - NOK | 0.0% |
2013 Q3 | - NOK | 0.0% |
2013 Q4 | - NOK | 0.0% |
2013 FY | - NOK | 0.0% |
2012 Q1 | - NOK | -100.0% |
2012 Q4 | - NOK | 0.0% |
2012 Q3 | - NOK | 0.0% |
2012 Q2 | - NOK | 0.0% |
2012 FY | - NOK | -100.0% |
2011 Q1 | - NOK | -100.0% |
2011 FY | 7.42 Million NOK | -28.93% |
2011 Q2 | - NOK | 0.0% |
2011 Q3 | - NOK | 0.0% |
2011 Q4 | 7.42 Million NOK | 0.0% |
2010 Q3 | 5.55 Million NOK | 0.0% |
2010 Q1 | - NOK | -100.0% |
2010 FY | 10.44 Million NOK | 21.27% |
2010 Q2 | - NOK | 0.0% |
2010 Q4 | 1.74 Million NOK | -68.64% |
2009 Q4 | 2.39 Million NOK | -13.79% |
2009 Q3 | 2.77 Million NOK | 0.0% |
2009 Q2 | - NOK | 0.0% |
2009 FY | 8.61 Million NOK | 16.9% |
2008 FY | 7.36 Million NOK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Arctic Bioscience AS | 33.75 Million NOK | 91.141% |
Aqua Bio Technology ASA | 1.55 Million NOK | -91.703% |
ArcticZymes Technologies ASA | 118.93 Million NOK | 97.486% |
BerGenBio ASA | 354 Thousand NOK | -744.633% |
Hofseth BioCare ASA | 194.87 Million NOK | 98.466% |
Thor Medical ASA | - NOK | -Infinity% |
Ultimovacs ASA | - NOK | -Infinity% |